OncoSec to Host Fourth Quarter and Year End Financial Results Conference Call on October 25, 2017 Oct 13, 2017 8:00am EDT
OncoSec to Present Updated Clinical and Immune Biomarker Data from its Monotherapy and Combination Therapy Studies with ImmunoPulse® IL-12 at the 9th World Congress of Melanoma - A Joint Meeting with the Society for Melanoma Research Oct 12, 2017 8:00am EDT
OncoSec Announces Acceptance of Late Breaking Abstract at Upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting 2017 Oct 11, 2017 5:03pm EDT
OncoSec Initiates Registration Directed Clinical Trial, KEYNOTE-695, of ImmunoPulse® IL-12 in Combination with Merck's KEYTRUDA® (pembrolizumab) Oct 10, 2017 8:00am EDT
OncoSec Presents Clinical Overview of Comprehensive Immune Monitoring Data Demonstrating Conversion of "Cold" Tumors to "Hot" Tumors with ImmunoPulse® IL-12 and Pembrolizumab Combination Therapy Sep 27, 2017 8:00am EDT
OncoSec Appoints Industry Leader Daniel J. O'Connor to its Board of Directors Sep 07, 2017 6:00am EDT
OncoSec Announces Presentations at Upcoming Investment and Scientific Conferences Sep 06, 2017 2:44pm EDT
OncoSec Appoints Industry Veteran Annalisa Jenkins MBBS, FRCP to Board of Directors Sep 05, 2017 6:00am EDT
OncoSec Announces Technology Access Program Agreement with Jounce Therapeutics, Inc. Jun 12, 2017 6:01am EDT
